Mind Medicine Q1 2024 GAAP EPS $(1.14) Misses $(0.53) Estimate
Portfolio Pulse from Benzinga Newsdesk
Mind Medicine (MNMD) reported a Q1 2024 GAAP EPS loss of $(1.14), missing the consensus estimate of $(0.53) by 115.09%. This represents a 75.38% increase in losses compared to the same period last year, where losses were $(0.65) per share.
May 08, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mind Medicine reported a significant miss in its Q1 2024 earnings, with losses per share of $(1.14), far exceeding the estimated $(0.53). This marks a substantial increase in losses from the previous year.
The significant miss in earnings and the substantial increase in losses compared to the previous year are likely to negatively impact investor sentiment and the stock price in the short term. The magnitude of the miss and the worsening financial performance compared to the same period last year highlight operational challenges that could concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100